

# Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

## [NCI-N87/TR](#)

RRID:CVCL\_IL03

Type: Cell Line

### Proper Citation

RRID:CVCL\_IL03

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_IL03](https://web.expasy.org/cellosaurus/CVCL_IL03)

**Proper Citation:** RRID:CVCL\_IL03

**Description:** Cell line NCI-N87/TR is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Gastric tubular adenocarcinoma

**Defining Citation:** [PMID:26108989](#)

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** NCI-N87/TR

**Cross References:** cancercellines:CVCL\_IL03, Wikidata:Q54908218

**ID:** CVCL\_IL03

**Hierarchy:** cvcl\_1603

**Record Creation Time:** 20220427T220841+0000

**Record Last Update:** 20260829T234744+0000

### Ratings and Alerts

No rating or validation information has been found for NCI-N87/TR.

No alerts have been found for NCI-N87/TR.

## Data and Source Information

**Source:** [CelloSaurus](#)

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. Cancer letters, 587, 216702.

Hu X, et al. (2023) Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer communications (London, England), 43(8), 909.

Wang J, et al. (2022) Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer research, 82(8), 1503.

McCombs JR, et al. (2021) Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy. International journal of pharmaceutics, 610, 121272.